Guopeng Pan

Guopeng Pan

Auto-generated profile, based on publicly available information

Guopeng Pan

Department of Pharmacology, School of Medicine, Jinan University, Guangzhou 510632, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YHYouwei Huang
Youwei Huang
FWFang Wang
Fang Wang
XLXi Lin
Xi Lin
QLQing Li
Qing Li
YLYuli Lu
Yuli Lu
HZHaipeng Zhang
Haipeng Zhang
Fatty acid oxidation (FAO) fuels many cancers. However, knowledge of pathways that drive FAO in cancer remains unclear. Here, we revealed that valosin-containing protein (VCP) upregulates FAO to promote colorectal cancer growth. Mechanistically, nuclear VCP binds to histone deacetylase 1 (HDAC1) and facilitates its degradation, thus promoting the transcription of FAO genes, including the rate-limiting enzyme carnitine palmitoyltransferase 1A ( CPT1A ). FAO is an alternative fuel for cancer cells in environments exhibiting limited glucose availability. We observed that a VCP inhibitor blocked the upregulation of FAO activity and CPT1A expression triggered by metformin in colorectal cancer (CRC) cells. Combined VCP inhibitor and metformin prove more effective than either agent alone in culture and in vivo. Our study illustrates the molecular mechanism underlying the regulation of FAO by nuclear VCP and demonstrates the potential therapeutic utility of VCP inhibitor and metformin combination treatment for colorectal cancer.

4 August 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
ZQZixi Qin
Zixi Qin
YHYouwei Huang
Youwei Huang
ZLZeying Li
Zeying Li
GPGuopeng Pan
Guopeng Pan
LZLiangying Zheng
Liangying Zheng
FXFan Xing
Fan Xing
Glioblastoma (GBM) is the deadliest form of brain cancer. It is a highly angiogenic and immunosuppressive malignancy. Although immune checkpoint blockade therapies have revolutionized treatment for many types of cancer, their therapeutic efficacy in GBM has been far less than expected or even ineffective. In this study, we found that the genomic signature of glioma-derived endothelial cells (GdEC) correlates with an immunosuppressive state and poor prognosis of patients with glioma. We established an in vitro model of GdEC differentiation for drug screening and used this to determine that cyclic adenosine monophosphate (cAMP) activators could effectively block GdEC formation by inducing oxidative stress. Furthermore, cAMP activators impaired GdEC differentiation in vivo, normalized the tumor vessels, and altered the tumor immune profile, especially increasing the influx and function of CD8+ effector T cells. Dual blockade of GdECs and PD-1 induced tumor regression and established antitumor immune memory. Thus, our study reveals that endothelial transdifferentiation of GBM shapes an endothelial immune cell barrier and supports the clinical development of combining GdEC blockade and immunotherapy for GBM. See related Spotlight by Lee et al., p. 1300


16 September 2024
Verified
Other
Open access
ZQZixi Qin
Zixi Qin
YHYouwei Huang
Youwei Huang
ZLZeying Li
Zeying Li
GPGuopeng Pan
Guopeng Pan
LZLiangying Zheng
Liangying Zheng
FXFan Xing
Fan Xing
Candidate drugs in the compound library

26 November 2025
Verified
Other
Open access
ZQZixi Qin
Zixi Qin
YHYouwei Huang
Youwei Huang
ZLZeying Li
Zeying Li
GPGuopeng Pan
Guopeng Pan
LZLiangying Zheng
Liangying Zheng
FXFan Xing
Fan Xing
Supplementary Table S1 from Glioblastoma Vascular Plasticity Limits Effector T-cell Infiltration and Is Blocked by cAMP Activation

4 October 2023
Verified
Other
Open access
ZQZixi Qin
Zixi Qin
YHYouwei Huang
Youwei Huang
ZLZeying Li
Zeying Li
GPGuopeng Pan
Guopeng Pan
LZLiangying Zheng
Liangying Zheng
FXFan Xing
Fan Xing
Glioblastoma (GBM) is the deadliest form of brain cancer. It is a highly angiogenic and immunosuppressive malignancy. Although immune checkpoint blockade therapies have revolutionized treatment for many types of cancer, their therapeutic efficacy in GBM has been far less than expected or even ineffective. In this study, we found that the genomic signature of glioma-derived endothelial cells (GdEC) correlates with an immunosuppressive state and poor prognosis of patients with glioma. We established an in vitro model of GdEC differentiation for drug screening and used this to determine that cyclic adenosine monophosphate (cAMP) activators could effectively block GdEC formation by inducing oxidative stress. Furthermore, cAMP activators impaired GdEC differentiation in vivo, normalized the tumor vessels, and altered the tumor immune profile, especially increasing the influx and function of CD8+ effector T cells. Dual blockade of GdECs and PD-1 induced tumor regression and established antitumor immune memory. Thus, our study reveals that endothelial transdifferentiation of GBM shapes an endothelial immune cell barrier and supports the clinical development of combining GdEC blockade and immunotherapy for GBM.See related Spotlight by Lee et al., p. 1300